miRNA Sequencing and Assay Market Report 2022: Rise in Adoption of RNA Sequencing Protocols in Biotechnology Research Drives Growth - ResearchAndMarkets.com
The "miRNA Sequencing and Assay Market Size, Share & Trends Analysis Report by Product & Service, by Technology, by Workflow, by Application, by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering
DUBLIN--(BUSINESS WIRE)--Dec 2, 2022--
The "miRNA Sequencing and Assay Market Size, Share & Trends Analysis Report by Product & Service, by Technology, by Workflow, by Application, by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global miRNA sequencing and assay market size is expected to reach USD 823.5 million by 2030. The market is expected to register a CAGR of 13.25% from 2022 to 2030 owing to the growing application areas of miRNA sequencing in the healthcare sector. For instance, various research studies stated that miRNAs can be efficiently used as biomarkers in the prognosis and diagnosis of cancer (cervical, ovarian, and breast), sepsis, cardiovascular diseases, and nervous system conditions. Thus, miRNA sequence analysis is significantly employed for gene regulation analysis in clinical disorders. For instance, an article published in frontiers, in March 2022, stated that blood-based miRNA biomarkers could be used to correlate brain-based miRNA expression.
Prominent players such as PerkinElmer Inc.; Illumina, Inc.; and Qiagen offer innovative sequencing products for several clinical applications. Furthermore, these companies have entered into several strategic initiatives with research institutes to expand the sequencing application in research studies. For instance, in January 2022, BIORCHESTRA, a South Korean biopharmaceutical company, entered into a partnership agreement with SK Biopharmaceuticals to accelerate research and development into novel therapeutic compounds that target miRNAs.
